Literature DB >> 1889983

Shortlasting, unilateral, neuralgiform headache attacks with conjunctival injection, tearing, and subclinical forehead sweating ("Sunct" syndrome): II. Changes in heart rate and arterial blood pressure during pain paroxysms.

P Kruszewski1, M L Fasano, A O Brubakk, J M Shen, T Sand, O Sjaastad.   

Abstract

The recently described "Sunct" syndrome is a rare picture of unilateral, shortlasting headache attacks accompanied by autonomic phenomena (conjunctival injection, tearing, etc.) on the symptomatic side. Heart rate and blood pressure were monitored in two elderly "Sunct" patients during and outside headache attacks. An ultrasound Doppler servo method was used for the non-invasive, continuous, beat-to-beat determination of instantaneous arterial blood pressure. In a third patient, systolic and diastolic blood pressure, both outside and during pain paroxysms, were assessed using the standard Korotkoff method. Heart rate was found to be significantly decreased during pain paroxysms. Systolic blood pressure was observed to be significantly increased during attacks, when compared with the inter-attack period, while a less consistent pattern was observed for diastolic blood pressure. Some of the changes in the cardiovascular system seemed to start prior to pain onset. Therefore, it seems unlikely that these changes were caused by pain activation of the sympathetic nervous system or the oculocardiac reflex.

Entities:  

Mesh:

Year:  1991        PMID: 1889983     DOI: 10.1111/j.1526-4610.1991.hed3106399.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  2 in total

1.  SUNCT syndrome: The materialization of a headache syndrome.

Authors:  Ottar Sjaastad
Journal:  Clin Ophthalmol       Date:  2008-09

2.  Shortlasting, Unilateral, Neuralgiform, Headache Attacks With Conjunctival Injection, Tearing, Sweating and Rhinorrhea: The Term and New View Points

Authors:  Fabio Antonaci; Torbjørn Fredriksen; Juan A Pareja; Ottar Sjaastad
Journal:  Front Neurol       Date:  2018-04-23       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.